I am a
Home I AM A Search Login

Papers of the Week


2022


Ther Adv Neurol Disord


15

Incidence, clinical spectrum, and immunotherapy of non-ischemic cerebral enhancing lesions after endovascular therapy.

Authors

Bayas A, Christ M, Berlis A, Naumann M, Ertl M, Joachimski F, Müller M, Welzel J, Gerdes L A, Seelos K, Maurer C
Ther Adv Neurol Disord. 2022; 15:17562864211072372.
PMID: 35126670.

Abstract

Symptomatic and asymptomatic delayed non-ischemic cerebral enhancing (NICE) lesions in magnetic resonance imaging (MRI) have been reported as a rare complication after endovascular therapy (EVT) in recent years with incidence rates between 0.05% and 0.9% in most studies. Information on long-term clinical course and immunotherapies is scarce or has not been reported in detail in the literature. Objective: Aims of our study were to assess the incidence of NICE lesions in patients after cerebral EVT over a period of more than 12 years, describe clinical and EVT characteristics, and immunotherapies applied.